Abstract
Systemic inflammatory rheumatic diseases are associated with an increased risk of malignancy, in particular of lymphoproliferative disorders. Chronic inflammation, due to the disease itself, generates a microenvironment able to promote cancer development, but it is still controversial whether immunosuppressive therapy may contribute to carcinogenesis. The aim of the study was to evaluate the risk of malignancy in 399 patients affected by rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis, all treated with either tumor necrosis factor α-inhibitors plus disease-modifying anti-rheumatic drugs (DMARDs) or DMARDs alone. The risk of malignancy in this cohort of patients, observed in the period between 2005 and 2011 at S. Andrea Hospital-Sapienza University of Rome, was compared with that of the general Italian population, matched for age, sex, and area of residence. Fourteen (3.5 %) malignancies, five of which were hematologic, have been observed. The overall cancer risk was not significantly increased in comparison to the general population, whereas the risk of hematologic malignancies appeared significantly higher in RA patients (SIR 4.94, 95 % CI 1.35–12.64), particularly in female gender (SIR 6.9, 0.95 % CI 1.88–17.66). No significant association between therapy and malignancy was demonstrated in RA patients.
Similar content being viewed by others
References
Turesson C, Matteson EL (2013) Malignancy as a comorbidity in rheumatic diseases. Rheumatology 52(1):5–14
Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD (2008) Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 58(1):82–87
Husni ME, Mease PJ (2010) Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 12(4):281–287
Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64(6):1035–1050
Gross RL, Schwartzman-Morris JS, Krathen M, Reed G, Chang H, Saunders KC, Fisher MC, Greenberg JD, Putterman C, Mease PJ, Gottlieb AB, Kremer JM, Broder A (2014) A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol 66(6):1472–1481
Westhovens I, Lories RJ, Westhovens R, Verschueren P, de Vlam K (2014) Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR). Clin Exp Rheumatol 32(1):71–76
Feltelius N, Ekbom A, Blomqvist P (2003) Cancer incidence among patients with ankylosing spondylitis in Sweden 1965–1995: a population based cohort study. Ann Rheum Dis 62(12):1185–1188
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899
Ponce RA, Gelzleichter T, Haggerty HG, Heidel S, Holdren MS, Lebrec H, Mellon RD, Pallardy M (2014) Immunomodulation and lymphoma in humans. J Immunotoxicol 11(1):1–12
Balkwill FR, Mantovani A (2012) Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22(1):33–40
Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361–371
Raval G, Mehta P (2010) TNF-α inhibitors: are they carcinogenic? Drug Healthc Patient Saf 2:241–247
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275–2285
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68(7):1177–1183
Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20(2):119–130
Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68(7):1136–1145
Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63(6):1479–1485
Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886–2895
Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P (2011) Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology 50(8):1431–1439
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308(9):898–908
Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, Hochberg MC, Qi K, Suissa S (2009) Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68(12):1819–1826
Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2012) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13(5):R141
Mariette X, Tubach F, Bagheri H, Bardet M, JBerthelot M, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P (2010) Lymphoma in patients treated with anti-TNF: results of the 3 year prospective French RATIO registry. Ann Rheum Dis 69(2):400–408
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54(3):692–701
Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD (2014) Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 43(4):489–497
Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, JFries F, Cooper NS et al (1988) “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis”. Arthritis Rheum 31:315–324
Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55–78
Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
Smith AC, von Eschenbach R, Wender, BT, Levin Byers D, Rothenberger D, Brooks W, Creasman C, Cohen C, Runowicz D, Saslow V, Cokkinides H, Eyre (2001) For the ACS Colorectal Cancer Advisory Committee, and the ACS Endometrial Cancer Advisory Committee. “American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001. Testing for early lung cancer detection”. CA Cancer J Clin 51: 38–75
Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C (2010) Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9(3):175–180
Nannini C, Cantini F, Niccoli L, Cassarà E, Salvarani C, Olivieri I, Lally EV (2009) Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 61(6):801–812
Jakob L, Metzler G, Chen KM, Garbe C (2011) Non-AIDS associated Kaposi’s sarcoma: clinical features and treatment outcome. PLoS One 6(4):e18397
Louthrenoo W, Kasitanon N, Mahanuphab P, Bhoopat L, Thongprasert S (2003) Kaposi’s sarcoma in rheumatic disease. Semin Arthritis Rheum 32:326–333
Nassar D, Schartz NE, Bouché C, Lévy A, Kerob D, Agbalika F, Lafaurie M, Lebbé C (2010) Kaposi’s sarcoma after long-acting steroids: time until remission and drug washout. Dermatology 220:159–163
Amadu V, Satta R, Montesu MA, Cottoni F (2012) Kaposi’s sarcoma associated with treatment with adalimumab. Dermatol Ther 25(6):619–620
Bret J, Hernandez J, Aquilina C, Zabraniecki L, Fournie B (2009) Kaposi’s disease in a patient on adalimumab for rheumatoid arthritis. Joint Bone Spine 76:721–722
Blay LE, Mouterde P, Barnetche T, Morel J, Combe B (2012) Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol 39(4):712–715
Ramiro S, Gaujoux-Viala C, Nam JL, JSmolen S, Buch M, Gossec L, van der Heijde D, van der Heijde K, Landewé R (2014) “Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis”. Ann Rheum Dis 73(3):529–535
Raaschou P, Simard JF, Holmqvist M, Askling J, ARTIS Study Group (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346:1939
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904
Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50(6):1740–1751
Callan MFC (2004) Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol 16:399–405
Balandraud N, Roudier J, Roudier C, Pharm D (2005) What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis antagonism in rheumatoid arthritis? Semin Arthritis Rheum 34:31–33
Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L (2004) Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16:254–261
Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J (2002) The investigators of the Club Rheumatismes et Inflammation, “Lymphoma in rheumatoid arthritis patients treated with methotrexate: a 3 year prospective study in France”. Blood 99:3909–3915
Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru J, Kishi K, Kanamori H, Higashihara M, Hotta T, Ishigatsubo Y (2007) Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 82:1106–1109
Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J (1996) Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14(6):1943–1949
Mo N, Muthu S, O’Sullivan M (2011) Regression of lymphoma after withdrawal of infliximab alone in an infliximab/methotrexate-treated RA patient. Rheumatology 50(4):808–810
Park SH, Kim CG, Kim JY, Choe JY (2008) Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int 28(5):475–477
Komatsuda A, Wakui H, Nimura T, Sawada K (2008) Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol 18(3):315–318
Thonhofer R, Gaugg M, Kriessmayr M, Neumann HJ, Erlacher L (2005) Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis 64(7):1098–1099
Bernatsky S, Lee JL, Rahme E (2007) Non-Hodgkin’s lymphoma-meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology 46:690–694
Hellgren K, Iliadou A, Rosenquist R, Feltelius N, Backlin C, Enblad G, Askling J, Baecklund E (2010) Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis 69(4):654–659
Solomon DH, Mercer E, Kavanaugh A (2012) Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 64(1):21–32
Conflict of interest
Authors declare that they have no conflict of interest.
Statement of human and animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the author.
Informed consent
Informed consent was obtained from all individuals participants included in the study.
Author information
Authors and Affiliations
Corresponding author
Additional information
M. Fantò and M. S. Peragallo equally contributed to the study.
Rights and permissions
About this article
Cite this article
Fantò, M., Peragallo, M.S., Pietrosanti, M. et al. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience. Intern Emerg Med 11, 31–40 (2016). https://doi.org/10.1007/s11739-015-1270-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-015-1270-0